Krukenberg Tumor – What You Need to Know

What is Krukenberg Tumor?

A Krukenberg tumor is a secondary (metastatic) ovarian cancer that most often originates from a primary gastrointestinal adenocarcinoma, especially gastric (stomach) cancer. The term was first used by Friedrich Krukenberg in 1896 to describe ovarian tumors that contain mucin‑producing signet‑ring cells. Unlike primary ovarian cancers, Krukenberg tumors are spread to the ovary through the bloodstream, lymphatic system, or peritoneal seeding. They tend to be bilateral (affect both ovaries) and are aggressive, often presenting at an advanced stage.

Because they are a manifestation of cancer elsewhere in the body, treatment and prognosis depend heavily on the location, stage, and biology of the original (primary) tumor.

Common Causes

Krukenberg tumors are not a disease in themselves; they are a pattern of metastasis. The most frequent primary sites include the following:

• Gastric (stomach) adenocarcinoma – the classic source, accounting for 50‑70% of cases.
• Colorectal cancer – especially cancers of the cecum, ascending colon, or rectum.
• Appendiceal mucinous neoplasm (e.g., pseudomyxoma peritonei).
• Breast carcinoma – typically invasive lobular type.
• Pancreatic adenocarcinoma.
• Gallbladder carcinoma.
• Small‑bowel (duodenal) adenocarcinoma.
• Urinary tract cancers (e.g., transitional cell carcinoma of the bladder).
• Rarely, thyroid or lung adenocarcinoma can metastasize to the ovary in a Krukenberg pattern.

Associated Symptoms

Because the tumor grows within the ovary, many symptoms mimic those of primary ovarian masses, but additional clues may point to an extra‑ovarian primary cancer.

• Abdominal or pelvic fullness / bloating
• Unexplained weight loss
• Persistent abdominal pain, often dull and diffuse
• Changes in bowel habits (diarrhea or constipation) – especially if the primary is colorectal
• Early satiety or nausea (common with gastric primary)
• Irregular menstrual bleeding or post‑menopausal bleeding
• Ascites (fluid accumulation in the abdomen)
• Pelvic mass palpable on exam
• General fatigue, anemia, or night sweats

When to See a Doctor

Any of the following warrants prompt medical evaluation:

• Sudden or progressive abdominal swelling or a persistent “full” feeling.
• New or worsening pelvic pain that does not improve with over‑the‑counter analgesics.
• Unexplained weight loss of >5% of body weight within 2–3 months.
• Vaginal bleeding after menopause or between periods.
• Persistent nausea, vomiting, or early satiety without other cause.
• Family history of gastric, colorectal, or other gastrointestinal cancers combined with any of the above signs.

Early evaluation improves the chance of identifying the primary tumor and planning appropriate therapy.

Diagnosis

Diagnosing a Krukenberg tumor involves a combination of imaging, laboratory tests, and tissue sampling.

1. Physical Examination

Gynecologic exam may reveal a firm, irregular ovarian mass; a bimanual pelvic exam can gauge size and mobility.

2. Imaging Studies

• Transvaginal ultrasound – first‑line to characterize ovarian morphology.
• CT scan of the abdomen/pelvis – evaluates bilateral ovarian involvement, ascites, and possible primary sites.
• MRI – provides superior soft‑tissue contrast for surgical planning.
• PET‑CT – useful for detecting occult primary tumors and distant metastases.

3. Laboratory Tests

• Complete blood count (CBC) – may show anemia.
• Liver function tests – assess hepatic involvement.
• Serum tumor markers:
  • CA‑125 – often elevated in ovarian involvement but not specific.
  • CEA, CA 19‑9 – helpful if gastrointestinal primary is suspected.
  • Carcinoembryonic antigen (CEA) may be markedly raised in colorectal origin.

4. Tissue Diagnosis

Definitive diagnosis requires histopathology:

• Image‑guided core needle biopsy of the ovarian mass.
• Laparoscopic or open surgical biopsy if percutaneous sampling is not feasible.
• Pathology will show characteristic mucin‑filled signet‑ring cells within a stromal background, confirming Krukenberg pattern.

5. Staging Work‑up

After confirming metastatic ovarian involvement, physicians search for the primary tumor using endoscopy (EGD, colonoscopy), bronchoscopy or other appropriate studies based on clinical clues.

Treatment Options

Treatment is multidisciplinary, involving oncologists, surgeons, radiologists, and palliative‑care specialists. The goals are to control the disease, relieve symptoms, and prolong survival.

1. Systemic Therapy

• Chemotherapy – Platinum‑based regimens (e.g., carboplatin + paclitaxel) are commonly used, mirroring treatment for primary ovarian carcinoma. Regimens are tailored to the primary tumor’s histology (e.g., FOLFOX for colorectal origin).
• Targeted therapy – HER2‑positive gastric cancers may benefit from trastuzumab; KRAS‑wildtype colorectal cancers may receive anti‑EGFR agents.
• Immunotherapy – PD‑1/PD‑L1 inhibitors are indicated for microsatellite‑instable (MSI‑H) or high tumor‑mutational‑burden cancers.

2. Surgical Management

Surgery can be curative in selected patients with limited disease or used for symptom relief (debulking, ovarian mass removal, ascites control). Decision‑making depends on:

• Extent of intra‑abdominal disease
• Patient’s performance status
• Resectability of the primary tumor

3. Radiation Therapy

Rarely used for ovarian metastases but may be considered for palliation of painful bone lesions or localized pelvic disease.

4. Supportive / Home Care

• Management of ascites – therapeutic paracentesis, diuretics, or peritoneovenous shunt.
• Pain control – acetaminophen, NSAIDs, or opioid analgesics as needed.
• Nutritional support – high‑protein diet, supplements, and dietitian guidance.
• Psychosocial support – counseling, support groups, and hospice services for end‑of‑life care.

Prevention Tips

Because Krukenberg tumors are metastases, primary prevention focuses on reducing the risk of the underlying cancers.

• Maintain a healthy diet rich in fruits, vegetables, whole grains, and lean protein; limit processed and smoked foods that increase gastric cancer risk.
• Avoid tobacco and excessive alcohol – both are linked to gastrointestinal malignancies.
• Regular screening according to age and risk:
  • Colorectal cancer: colonoscopy every 10 years beginning at age 45 (or earlier with family history).
  • Gastric cancer: endoscopic screening in high‑risk regions (East Asia) or for individuals with chronic H. pylori infection.
  • Breast cancer: mammography starting at 40–45 years, with MRI for high‑risk women.
• Manage Helicobacter pylori infection – eradication reduces gastric cancer incidence.
• Stay up‑to‑date with vaccinations (e.g., HPV, Hepatitis B) that can lower risk of some cancers.
• Maintain a healthy weight and engage in regular physical activity – both lower overall cancer risk.

Emergency Warning Signs

Key Take‑aways

Krukenberg tumor is a sign that a cancer elsewhere in the body has spread to the ovaries. Early recognition of the associated symptoms and prompt evaluation can uncover the primary malignancy when it may still be treatable. While prevention of the metastatic event focuses on reducing risk for gastric, colorectal, breast, and other adenocarcinomas, treatment requires a coordinated, personalized approach that blends systemic therapy, surgery, and supportive care. If you notice any concerning abdominal or pelvic changes, seek medical attention without delay.

---

References:

• Mayo Clinic. “Krukenberg tumor.” Accessed 2024.
• Cleveland Clinic. “Metastatic ovarian cancer (Krukenberg tumor).” 2023.
• National Cancer Institute. “Gastric Cancer Treatment (PDQ®)”. 2024.
• World Health Organization. “Cancer prevention guidelines.” 2022.
• American Society of Clinical Oncology. “Management of metastatic gastrointestinal cancer.” 2023.